Table 1

Population characteristics at baseline and clinical outcomes (n=354) compared with the previous study 1998–1999 (n=291)

ParametersPeriod 2020–2021
(n=354)		Period 1998–1999
(n=291)		P value
Populations characteristics
 Sex ratio (male/female)1.031.090.99
 Age (years)51±2139±180.008
 Right eye/left eye0.970.840.37
 Hospitalisation time (days)6.0 (0–41)9.0 (3-60)<0.0001
 Initial visual acuity (logMAR)1.64±0.820.79±1.0<0.0001
 Referred to the emergency unit168 (47%)72 (24%)<0.0001
 First symptoms-to-first examination time (days)4.4±6.4NA
Risk factors
 Contact lens wear160 (45%)151 (50%)0.25
 Ocular surface disease88 (25%)64 (21%)0.39
 Systemic disease77 (22%)51 (17%)0.13
 Ocular trauma42 (12%)45 (15%)0.24
 Ocular surgery31 (9%)12 (4%)0.004
 No risk factors17 (5%)28 (9%)0.02
Infiltrate characteristics<0.0001
 Area (mm2)
  <5158 (45%)123 (42%)
  5–15104 (29%)115 (38%)
  >1592 (26%)62 (20%)
 Depth<0.0001
  <1/3129 (36%)232 (77%)
  1/3–2/3147 (42%)39 (13%)
  >2/378 (22%)29 (10%)
Anterior chamber inflammation
 Tyndall223 (63%)73 (24.4%)<0.0001
  1+66 (19.0%)NA
  2+81 (23.0%)NA
  3+44 (12.0%)NA
  4+32 (9.0%)NA
 Hypopion118 (33%)18 (6%)<0.0001
Neovascularisation54 (15%)35 (12%)0.03
Perforation18 (5%)NA
Prior treatment
 Topical antibiotics125 (35%)72 (24%)0.002
 Topical steroids19 (5.4%)9 (3.1%)0.16
Positive microbiological identification292 (82%)204 (68%)<0.0001
Treatment
 Mean treatment time49.0±44.9 daysNA
 Surgical treatment
  Amniotic membrane transplantation78 (22%)NA
  Therapeutic penetrating keratoplasty13 (4%)2 (0.6%)0.01
  Evisceration3 (0.8%)2 (0.6%)0.79
Outcomes
 Mean follow-up time (days)117.9±165.390
 Final visual acuity (logMAR)0.82±0.94NA

  • Shown are the number (percentage) and mean (±SD).

  • NA, not available.